Study of BGG492 in Patients With Chronic Subjective Tinnitus

NCT01302873 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 96

Last updated 2017-03-22

No results posted yet for this study

Summary

This study will assess the efficacy of a two week treatment with BGG492 in patients with chronic subjective Tinnitus.

Conditions

  • Chronic Subjective Tinnitus

Interventions

DRUG

BGG492A

DRUG

BGG492A

Sponsors & Collaborators

Principal Investigators

  • Novartis Pharmaceuticals · Novartis Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-01-31
Completion
2012-01-31

Countries

  • Germany
  • Netherlands

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01302873 on ClinicalTrials.gov